

The APAC Biopharmaceutical market is growing at a compound annual growth rate (CAGR) of more than 10%, but regulatory approval to products launch is still a challenge for many companies to act early and move fast into country markets.
However, APAC markets remain attractive due to the fast-improving regulatory approval and market access. Hence, join us on this webinar to learn about the key success factors in selecting target-to-go countries based on regulatory agility and advancement in their access pathways. Furthermore, as the second largest pharmaceutical market globally, China, is currently undergoing major transformations that can create complexity and opportunities for companies to enter. The session will cover the recent trends of market evolvement, access environment and successful cases for commercialization in the China market.
Will Zhao
Principal, China Management Consulting, IQVIA
Luke Willbourn
Associate Principal, Consulting Services APAC, IQVIA
Sherry Wang
Principal, Head of Commercial Regulatory Services, IQVIA